Jubilant Pharmova (NSE:JUBLPHARMA, BOM:530019) said its board has approved the transfer of its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary Jubilant Biosys on a slump sale basis, according to a Thursday filing.
The transaction is expected to be completed by Sept. 1, subject to approvals from lenders and shareholders.
The consideration, yet to be finalized, will primarily be settled through share issuance under the terms of the business transfer agreement, the company said in the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。